PharmaEssentia Corporation (TPE:6446)

Market Cap	495.25B +172.5%
Revenue (ttm)	20.75B +64.2%
Net Income	7.63B +88.3%
EPS	18.50 +88.0%
Shares Out	414.43M
PE Ratio	64.60
Forward PE	38.42
Dividend	1.35 (0.11%)
Ex-Dividend Date	Jul 9, 2026

Volume	2,144,921
Open	1,205.00
Previous Close	1,195.00
Day's Range	1,185.00 - 1,215.00
52-Week Range	407.92 - 1,645.00
Beta	0.65
Analysts	Buy
Price Target	1,397.26 (+15.96%)
Earnings Date	Nov 9, 2026

About PharmaEssentia

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and imm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 131
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6446

Financial Performance

In 2025, PharmaEssentia's revenue was 15.63 billion, an increase of 60.61% compared to the previous year's 9.73 billion. Earnings were 5.05 billion, an increase of 70.13%.

Analyst Summary

According to 8 analysts, the average rating for 6446 stock is "Buy." The 12-month stock price target is $1,397, which is an increase of 15.96% from the latest price.

Price Target

$1,397

(15.96% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error